ALK plus NSCLC ALK Inhibitors symbolize Progress in Cancer Medicine

被引：0
|
作者：
Kohl, Angelika
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [31] Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
    Iannantuono, Giovanni Maria
    Riondino, Silvia
    Sganga, Stefano
    Roselli, Mario
    Torino, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [32] ESMO 2023 Adjuvant alectinib in operable ALK plus NSCLC, precision medicine in CUP syndrome
    Freyer, Martina
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [33] MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC
    Fang, Wenfeng
    Gan, Jiadi
    Hong, Shaodong
    Lu, Feng
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : E148 - E151
  • [34] Real-World Treatment Sequencing and Impact on Outcomes in ALK-Positive (ALK plus ) NoneSmall Cell Lung Cancer (NSCLC)
    Wan, Y.
    Elliott, J.
    Young, M.
    Yin, Y.
    Arnaoutakis, K.
    Leventakos, K.
    Lin, H. M.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E33 - E34
  • [35] ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
    Moskovitz, Mor
    Dudnik, Elizabeth
    Shamai, Sivan
    Rotenberg, Yakir
    Popovich-Hadari, Noa
    Wollner, Mira
    Zer, Alona
    Gottfried, Maya
    Mishaeli, Moshe
    Rosenberg, Shoshana Keren
    Onn, Amir
    Merimsky, Ofer
    Urban, Damien
    Peled, Nir
    Maimon, Natalie
    Bar, Jair
    ONCOLOGIST, 2022, 27 (01): : E76 - E84
  • [36] Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC
    Law, H.
    King, J. C.
    Lin, H. M.
    Curran, E.
    Wiens, J.
    Cruz, L.
    Blender, J.
    Venanzi, E. S.
    Schenk, E.
    Lin, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S113 - S114
  • [37] A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
    Sampson, Josephina
    Ju, Hyun-min
    Song, Ji-young
    Fry, Andrew M.
    Bayliss, Richard
    Choi, Jene
    CANCERS, 2022, 14 (03)
  • [38] A Prospective Multicenter Study for ALK IHC plus Metastasized NSCLC
    Thunnissen, Erik
    Skov, Bg
    Sorensen, Jens
    Mellemgaard, Anders
    Groen, H. J. M.
    Schuuring, Ed
    Timens, Wim
    Heuvel, Michel V. D.
    De Jong, J.
    Monkhorst, Kim
    De Langen, Joop
    Van der Drift, Miep
    Looijen-Salamon, Monika
    Dingemans, Anne-Marie
    Speel, Ernst-Jan M.
    Samii, Suzy
    Duplaquet, F.
    Weynand, Birgit
    Durando, X.
    Penault-Llorca, Frederique
    Pauwels, Patrick
    Kerr, Keith
    Nicolson, Marianne
    Finn, Stephen P.
    Schildgen, O.
    Bubendorf, Lukas
    Rohtschild, S.
    Hiemstra, Annemieke
    Witte, Birgit
    Smit, Egbert
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S649 - S649
  • [39] Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
    Wakelee, H.
    Sanborn, R.
    Nieva, J.
    Waqar, S.
    Brzezniak, C.
    Bauman, J.
    Neal, J.
    Dukart, G.
    Tan, F.
    Harrow, K.
    Liang, C.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1826 - S1826
  • [40] Diverse Characteristics of ALK plus NSCLC Patients in the United States
    Bendaly, Edmond
    Sasane, Medha
    Zhang, Jie
    Swallow, Elyse
    Macalalad, Alexander R.
    Patel, Dony
    Kageleiry, Andrew
    Galebach, Philip
    Kercheval, Jacquelyn
    Stein, Karen
    Guerin, Annie
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S376
12345